Loading
Adding cisplatin during radiotherapy and chemotherapy afterwards more than doubled the chance of being alive without disease three years later compared with radiotherapy alone, making chemoradiotherapy the standard for advanced nasopharyngeal cancer.
US Intergroup randomised phase 3 trial of patients with stage III to IV nasopharyngeal carcinoma comparing radiotherapy alone with radiotherapy plus concurrent cisplatin followed by three cycles of adjuvant cisplatin and fluorouracil; 147 patients were analysed after early closure for efficacy.
Three-year progression-free survival was 69 percent with chemoradiotherapy against 24 percent with radiotherapy, and overall survival 76 percent against 46 percent. The result established concurrent cisplatin with radiotherapy as the backbone of treatment worldwide.
Concurrent cisplatin with radiotherapy is the foundation of treatment for locoregionally advanced nasopharyngeal carcinoma; later trials in endemic regions refined the role of induction and adjuvant chemotherapy.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Journal of Clinical Oncology, Cisplatin.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Cisplatin.
Shares Fluorouracil (5-FU), Journal of Clinical Oncology, Cisplatin.
Shares Fluorouracil (5-FU), Cisplatin.
Shares Fluorouracil (5-FU), Cisplatin.
Shares Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA), Cisplatin.
Shares Fluorouracil (5-FU), Cisplatin.
Shares Fluorouracil (5-FU), Cisplatin.